Diabetes is associated with the risk of NASH
A study in this month's issue of Hepatology investigates the
association between diabetes, family history of diabetes, and risk of
nonalcoholic steatohepatitis and fibrosis.
Previous studies have shown familial aggregation of insulin resistance and
nonalcoholic fatty liver disease (NAFLD).
Dr Rohit Loomba and colleagues from California aimed to
examine whether family history of diabetes mellitus is associated with
nonalcoholic steatohepatitis (NASH) and fibrosis in patients with NAFLD.
The team performed a cross-sectional analysis in participants of the NAFLD
Database study and PIVENS trial who had available data on family history of
diabetes mellitus.
The researchers evaluated 169 patients, with mean age of 50 years and body
mass index of 34 kg/m2, were included.
The team found that 30% had diabetes mellitus, and 56% had a family history
of diabetes mellitus.
The researchers observed that both personal history of diabetes mellitus and
family history of diabetes mellitus were significantly associated with NASH,
with an odds ratio of 1.9, and 1.5, and any fibrosis with an odds ratio of 3.3,
and 1.66, respectively.
When the models were adjusted for age, sex, BMI, ethnicity, and metabolic
traits, the association between diabetes and family history of diabetes mellitus
with NASH showed an increased adjusted odds ratio of 1.8, and 1.3,
respectively.
With any fibrosis, the significant adjusted odds ratio was 2.6, and 1.4 for a
personal history with diabetes and family history of diabetes mellitus,
respectively.
After excluding patients with personal history of diabetes, family history of
diabetes mellitus was significantly associated with the presence of NASH and any
fibrosis with an adjusted odss ratio of about 1.5 for both.
Dr Loomba's team concludes, "Diabetes is strongly associated with risk of
NASH, fibrosis, and advanced fibrosis."
"Family history of diabetes, especially among nondiabetics, is associated
with NASH and fibrosis in NAFLD."
Hepatology 2012: 56(3): 943–951
12 September 2012
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment